Regencell’s Chief Business Officer Holds Firm as Shares Surge 12.98%‑Week‑High—Insider Confidence Signals Potential Upside Despite Volatility

Insider Holdings: A Quiet Signal from Regencell’s Top Executive

On March 18, 2026, Chief Business Officer AU YAT‑PUI filed a form 3 reporting a holding of 581,514 ordinary shares. The transaction shows no purchase or sale, but it confirms that YAT‑PUI’s stake remains unchanged at the current market price of $27.18. While the filing itself carries no immediate trading activity, the fact that the chief business officer has maintained a sizable position amid a period of rising share price (12.98 % weekly gain) may be interpreted by investors as an endorsement of the company’s short‑term outlook.

What the Holding Means for Investors

Regencell’s share price has surged dramatically over the past year—up more than 2,100 % from the 52‑week low—yet it remains volatile, reflected in a negative P/E ratio of –3,164. The company’s business model, centered on traditional medicine for neurocognitive disorders, is niche and long‑term. A holding of 581,514 shares by a senior executive, particularly one tasked with commercial strategy, suggests confidence that the firm will capitalize on its pipeline and global reach. For investors, the lack of a sell‑off by YAT‑PUI may provide a “buy the rumor, sell the news” cushion, indicating that insiders are not rushing to liquidate positions amid short‑term gains.

A Profile of AU YAT‑PUI

YAT‑PUI’s insider file history is sparse—only the current holding appears on record. This pattern aligns with a “quiet‑holder” profile: a senior executive who holds shares long‑term and does not engage in frequent trading. Compared to peers such as COO CHAN HO YAU or CEO AU YAT‑GAI (who also reported holdings), YAT‑PUI’s lack of trading activity signals a stable, long‑term investment horizon. In the broader context, the company’s insider activity is low: eight recent filings across the board, each showing a single holding. This suggests a tightly controlled equity structure, potentially limiting dilution and preserving insider confidence.

Implications for Regencell’s Future

The current filing, coupled with a high social‑media buzz (over 400 % communication intensity) and a neutral sentiment score, indicates that market attention is high but not driven by negative news. With the company’s valuation hovering at $11.5 billion and a robust 52‑week high of $83.60, the market appears to be pricing in significant upside potential. If insiders remain committed, this could reinforce investor confidence in Regencell’s strategic initiatives—particularly its expansion into new therapeutic areas and international licensing deals. However, the negative P/E and steep price volatility caution that the stock remains speculative; prudent investors should monitor upcoming clinical milestones and regulatory approvals for confirmation of the company’s value proposition.